MAKO Surgical (Nasdaq: MAKO ) reported earnings on Nov. 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), MAKO Surgical beat expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue increased significantly and GAAP loss per share shrank.
Gross margins dropped, operating margins increased, net margins grew.
MAKO Surgical recorded revenue of $29.2 million. The 11 analysts polled by S&P Capital IQ predicted a top line of $27.5 million on the same basis. GAAP reported sales were 46% higher than the prior-year quarter's $20.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.15. The nine earnings estimates compiled by S&P Capital IQ predicted -$0.16 per share. GAAP EPS were -$0.15 for Q3 against -$0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 59.0%, 680 basis points worse than the prior-year quarter. Operating margin was -32.0%, 1,590 basis points better than the prior-year quarter. Net margin was -22.5%, 2,570 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $36.1 million. On the bottom line, the average EPS estimate is -$0.10.
Next year's average estimate for revenue is $107.0 million. The average EPS estimate is -$0.74.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,170 members out of 1,213 rating the stock outperform, and 43 members rating it underperform. Among 253 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 244 give MAKO Surgical a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MAKO Surgical is hold, with an average price target of $17.86.
- Add MAKO Surgical to My Watchlist.